Rare disease infrastructure is a platform, not a program.
Pharma²⁸ is building the operating layer that connects biotech innovation to real-world access in one of the world's most under-executed rare disease geographies.
Each program strengthens the next. Cohorts compound. Investigator networks deepen. Data assets grow. Regulatory pathways become repeatable. The platform's value is cumulative.
Underused geography
Brazil remains structurally undersupplied for rare disease infrastructure.
Cohort economics
Real-world evidence and identification reduce program timelines and cost.
Corridor advantage
Boston fluency, Brazilian execution — few players operate both sides.
Platform durability
Data and access assets outlast a single therapy.
- 01
Operating platform
Regulatory, clinical, access execution.
- 02
Technology asset
Structured clinical data and intelligence.
- 03
Cohort & evidence base
Longitudinal populations across rare disease.
- 04
Corridor position
Boston–Brazil connectivity, institutionalized.
Rare & ultra-rare focus
Programs anchored in high unmet medical need.
International potential
Innovative therapies with a credible cross-border pathway.
Clinical validation
Opportunities for evidence generation and cohort access.
Academic collaboration
Alignment with tertiary and research institutions.
Responsible access
A commitment to scientific rigor and ethical patient reach.
Long-term value
Assets — data, evidence, relationships — that compound.
We do not overstate. We do not project cures. Our disclosures reflect the operating discipline of the company.
Building rare disease infrastructure, together.
If you are advancing a therapy, investing in the space, running a clinical program or coordinating patient identification — start a conversation with us.